About
ImmunoEdge develops a low-loss immunopeptidomics platform using novel capture chemistry to recover HLA-presented tumor peptides from ultra-low-input biopsies, enabling broader immune target discovery for next-generation immunotherapies and patient monitoring.
Explore ImmunoEdge's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.